Crucell, NV

Company secures patent license from NIH to commercialize Ebola vaccines

Published in Lab Law Weekly, April 22nd, 2005

Dutch biotechnology company Crucell, NV, (CRXL) announced that it has obtained an exclusive license to certain patents of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services, to develop and commercialize recombinant vaccines against Ebola.

The patents cover valuable vaccine components, such as the Ebola antigens and vectors.

In addition, the license covers "one-shot" emergency vaccination strategies that have proven to be effective in relevant animal models.

"This license uniquely positions Crucell to commercialize an Ebola vaccine," said Crucell CEO Dr. Ronald Brus. "It...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2005-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry